Op-T-Mune, Inc
Biotech · Private
CD40-targeting therapeutic molecules to block the CD40–CD154 pathway and reverse insulin loss in Type 1 Diabetes
- Grants
- $4.2M
- 8 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20162017201820192020
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Developing a small peptide to control autoimmune inflammation in type diabetes | $297,387 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Developing a small peptide to control autoimmune inflammation in type 1 diabetes | $297,387 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Clinical Screening Platform for Type 1 Diabetes | $421,182 | |
| Federal grant | Department of Health and Human Services · Phase I · Screening for the autoimmune component of multiple sclerosis | $299,002 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Clinical Screening Platform for Type 1 Diabetes | $561,109 | |
| Federal grant | Department of Health and Human Services · Phase II · Developing a Small Peptide to Control Autoimmune Inflammation In Type 1 Diabetes | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Clinical Screening Platform for Type 1 Diabetes | $594,177 | |
| Federal grant | Department of Health and Human Services · Phase II · Developing a Small Peptide to Control Autoimmune Inflammation In Type 1 Diabetes | $764,501 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1412 | Mirai Bio | — | — |
| 1413 | Abcombi Biosciences Inc | — | — |
| 1414 | DeNovoTherapies LLC | — | — |
| 1415 | Op-T-Mune, Inc | — | — |
| 1416 | COGENTIS THERAPEUTICS INC | — | — |
| 1417 | Omega Biosystems Incorporated | — | — |
| 1418 | Omm Scientific, Inc | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.